A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With Transfusion-dependent α-Thalassemia by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral Vector (GMCN-508A Drug Product)
Latest Information Update: 21 Apr 2023
At a glance
- Drugs GMCN 508A (Primary)
- Indications Alpha-thalassaemia
- Focus Therapeutic Use
Most Recent Events
- 16 Apr 2023 Planned primary completion date changed from 1 Jun 2028 to 1 Aug 2028.
- 16 Apr 2023 Status changed from not yet recruiting to recruiting.
- 14 Mar 2023 New trial record